anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to methods and compositions for the treatment of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. The methods of the invention involve the administration, in a delayed-release capsule or tablet containing a mixture of peppermint oil and chlorophyll. Other ingredients that may also be effective treatments may be included. This method may be useful as a new and safer treatment for IBS and other functional gastrointestinal disorders. The action of the peppermint oil is effective as a modulator of gastrointestinal motility and sensation. Chlorophyll may improve bowel activity by stimulation of secretion and motility. This is the first description of this unique mixture of these natural products for the treatment of gastrointestinal conditions.
The Student Diagnosis Form, Self-Confidence/Efficacy Scale in Patient Intervention and Perceived Stress Scale will be applied first to this group. Then, face-to-face theoretical training will be given. Post-tests will be administered 2 weeks after the theoretical training.
Preterm infants are at high risk of developing neonatal sepsis. γδ T cells are thought to be an important set of effector cells in neonates. Here, γδ T cells were investigated in a longitudinal cohort of preterm neonates using next-generation sequencing, flow cytometry, and functional assays. During the first year of life, the Vγ9Vδ2 T cell subset showed dynamic phenotypic changes and elevated levels of fetal-derived Vγ9Vδ2 T cells were evident in infants with sepsis. Single-cell transcriptomics identified HLA-DRhiCD83+ γδ T cells in neonatal sepsis, which expressed genes related to antigen presentation. In vitro assays showed that CD83 was expressed on activated Vγ9Vδ2 T cells in preterm and term neonates, but not in adults. In contrast, activation of adult Vγ9Vδ2 T cells enhanced CD86 expression, which was presumably the key receptor to induce CD4 T cell proliferation. Together, we provide a map of the maturation of γδ T cells after preterm birth and highlight their phenotypic diversity in infections.
Subjects will receive GW685698X 800 microgram (mcg) single inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
BACKGROUND: The multifaceted nature of Fibromyalgia syndrome (FM) symptoms has been explored through clusters analysis.
OBJECTIVE: To synthesize the cluster research on FM (variables, methods, patient subgroups, and evaluation metrics).
METHODS: We performed a systematic review following the PRISMA recommendations. Independent searches were performed on PubMed, Embase, Web of Science, and Cochrane Central, employing the terms "fibromyalgia" and "cluster analysis". We included studies dated to January 2024, using the cluster analysis to assess any physical, psychological, clinical, or biomedical variables in FM subjects, and descriptively synthesized the studies in terms of design, cluster method, and resulting patient profiles.
RESULTS: We included 39 studies. Most with a cross-sectional design aiming to classify subsets based on the severity, adjustment, symptomatic manifestations, psychological profiles, and response to treatment, based on demographic and clinical variables. Two to four different profiles were found according to the levels of severity and adjustment to FMS. According to symptom manifestation, two to three clusters described the predominance of pain versus fatigue, and thermal pain sensitivity (less versus more sensitive). Other clusters revealed profiles of personality (pathological versus non-pathological) and psychological vulnerability (suicidal ideation). Additionally, studies identified different responses to treatment (pharmacological and multimodal).
CONCLUSION: Several profiles exist within FMS population, which point out to the need for specific treatment options given the different profiles and an efficient allocation of healthcare resources. We notice a need towards more objective measures, and the validation of the cluster results. Further research might investigate some of the assumptions of these findings, which are further discussed in this paper.
The invention provides novel peptide derivatives which are designed to deliver pharmacologically active peptides into the central nervous system by sequential metabolism. The peptide is placed in a molecular environment which disguises its peptide nature and provides biolabile, lipophilic functions to penetrate the blood-brain barrier by passive transport. The design incorporates a dihydropyridine-type redox targetor moiety, an amino acid or di- or -tripeptide spacer inserted between the targetor and N-terminal amino acid unit of the peptide and a bulky, lipophilic substituent protecting the C-terminal amino acid unit of the peptide. The dihydropyridine-type targetor undergoes an enzymatically mediated oxidation to a hydrophilic, membrane-impermeable pyridinium salt. That polar targetor-peptide conjugate is trapped behind the lipoidal blood-brain barrier. Over time, cleavage of the lipophilic ester from the peptide by esterase and or lipase enzymes and enzymatic cleavage of the targetor-spacer from the peptide results in release of the desired peptide in the brain.
PURPOSE: A Liriope platyphylla Wang et Tang seed extract for skin whitening is provided to remove DPPH and tyrosinase. CONSTITUTION: A cosmetic composition for skin whitening contains Liriope platyphylla Wang et Tang seed extract. The cosmetic composition also contains anthocyanine colorant of chemical formula 1 as an active ingredient. In chemical formula 1, R1 is OH or OCH3; and R2 is H, OH, or OCH. The extract is isolated using water, low alcohol of 1-4 carbon atoms or mixture thereof. The composition is manufactured in the form of a skin, lotion, cream, essence, nutrition lotion, patch, or pack. The cosmetic additive for skin whitening contains the extract.
Neuropathic pain is chronic pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain, with a high incidence and complex pathogenesis, is one of the most significant areas of clinical medicine and basic research. Currently, prescribed treatments are still unsatisfactory or have limited effectiveness. A medicinal preparation is required that relieves the neuropathic pain and prolongs action time, which has not yet been discovered. In this study, MIL-101 (Fe) was employed as a drug carrier to regulate the release of diclofenac sodium, thereby achieving the effect of analgesia and sustained release. The release curves demonstrated that diclofenac sodium could be continuously released from MIL-101 (Fe) for more than 48 h. There was no toxicity in vitro and in vivo, and the safety of MIL-101 (Fe) was confirmed by hematoxylin and eosin as well as ELISA tests in vivo. The results of behavioral testing, pharmacokinetics, and RNA sequencing analysis showed that MIL-101 (Fe) loaded with diclofenac sodium could enhance the mechanical withdrawal threshold and alleviate cold allodynia induced by Spared Nerve Injury, prolonging the work time by three days. The results indicated that MIL-101 (Fe) exhibited excellent biocompatibility, while the MIL-101 (Fe)-DS demonstrated analgesic and controlled-release properties. These findings provide a scientific foundation for the clinical management of neuropathic pain and the development of a novel formulation.
Orally administrable compsns. for binding phosphates in the gastrointestinal tract of uraemic patients are prepd. from an Al cpd. (I), esp. Al(OH)3, and a fat or oil (II), and are characterised by producing and/or maintaining a low Al level in the serum of uraemic patients. The (I):(II) ratio is at least 1:200, pref. 1:4. (II) is an oil or fat which is digested or attacked in the neutral or alkaline parts of the gastrointestinal tract but not in the acidic parts, (stomach and duodenum).
PURPOSE: The six-minute walk test (6MWT) can assess walking function but is time-consuming. We investigate the correlation of performance over the first two minutes of the 6MWT (2MWT#) and the 6MWT. We also evaluate the 2MWT#'s ability to predict 6MWT results, assess correlations to secondary explanatory outcomes, and assess the ability to discriminate between clinical subgroups.
MATERIAL AND METHODS: A cross-sectional study of 124 participants with LBP. Correlations between the 2MWT# and 6MWT and secondary outcomes were evaluated using the Pearson product-moment correlation coefficient. The predictive ability of the 2MWT# was defined as the residual distance between the observed 6MWT and three times the 2MWT#. Differences between clinical subgroups were evaluated using the Wilcoxon rank test.
RESULTS: The 2MWT# and 6MWT correlated highly (r = 83, 95% CI 0.76 - 0.87). The 2MWT# overestimated 6MWT results with 46.8 meters (SD 67.0). Both tests correlated with secondary outcomes and discriminated similarly between clinical subgroups.
CONCLUSIONS: The 2MWT# correlates highly with 6MWT but overestimates the observed 6MWT by 9%. Because it is shorter, possibly less burdensome, and with little or no loss of discriminatory ability, we consider it a legitimate alternative to the 6MWT in patients with LBP.Implications for rehabilitationWalking function is often affected in patients with low back pain (LBP).The six-minute walk test (6MWT) is frequently used to assess walking function but is time-consuming.A shorter two-minute walk test is a legitimate alternative in patients with LBP as it correlates highly with the 6MWT and has little or no loss of discriminatory ability between clinical subgroups.
Aqueous detergent preparations containing 1-20 wt. % of a condensation product of fatty acids with 12-22 carbon atoms and water-soluble oligo- and/or polypeptides and their water-soluble salts, and 1-20 wt. % of an alkyl glycoside are characterized by their excellent foaming capacity and increased viscosity or ease of thickening on addition of 1-8 wt. % of an amphoteric or zwitterionic tenside and/or 0.1-5 wt. % of a water-soluble, inorganic electrolytic salt, e.g. a chloride or sulphate of an alkali metal or magnesium.
The invention relates to a composition for strengthening an immune regulation function in a human body and applications thereof. The composition comprises effective components of panax japonicus saponin and panax japonicus polysaccharide or the effective components and an acceptable carrier on a health medicament, health food, health tea, health wine or a beverage. The composition has the function of improving the immune function of an immunocompromised mouse. In an animal model with a weak immune system caused by cyclophosphamide (Cy), the composition can enhance the spleen index of the immunocompromised mouse, enhance the proportions of CD<4+> to CD<8+> and B lymphocytes to NK cells, and increase the content of cell factors IL-2 and IFN-gamma. The composition enhances the medicament effect and the medical value of panax japonicus; therefore, the planting of medicinal materials and the development of medicaments can be promoted. The composition has better social and economic benefits.
Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
The invention discloses a fungus medicament for preventing postoperative cancer recurrence and a production method thereof. The fungus medicament for preventing postoperative cancer recurrence is prepared by the following raw materials in parts by weight: 23 parts of mythic fungus wall-broken spore powder, 13 parts of mythic fungus extract, 2 parts of agaricus brasiliensis extract, 3 parts of polyporus extract, 1 part of cordyceps sinensis extract, 12 parts of hedyotis diffusa extract and 15 parts of barbat skullcap extract; also the fungus medicament additionally comprises 1 part of ginseng extract and 5 parts of dog meat extract. The production method comprises: uniformly mixing the above extracts with mythic fungus wall-broken spore powder, drying, pulverizing and processing into capsules. The key point of the fungus medicament of the invention is that: according to the theories of traditional Chinese medicine, traditional Chinese medicine syndrome differentiation treatment and 'monarch and minister, assistant and guide', the above six traditional Chinese medicines are subjected to scientific compatibility, so that an effective medicine combination is established. Mice experiments prove that the fungus medicament has substantial cancer inhibiting effect and almost does not have any toxic and side effects on human body. The advantage that the fungus medicament belongs to a nontoxic immunization activator is precisely not owned by many anticancer cancer-treating chemotherapeutic medicaments and other immunization activators.
Mathematical modeling plays a crucial role in understanding and combating infectious diseases, offering predictive insights into disease spread and the impact of vaccination strategies. This paper explored the significance of mathematical modeling in epidemic control efforts, focusing on the interplay between vaccination strategies, disease transmission rates, and population immunity. To facilitate meaningful comparisons of vaccination strategies, we maintained a consistent framework by fixing the vaccination capacity to vary from 10 to 100% of the total population. As an example, at a 50% vaccination capacity, the pulse strategy averted approximately 45.61% of deaths, while continuous and hybrid strategies averted around 45.18 and 45.69%, respectively. Sensitivity analysis further indicated that continuous vaccination has a more direct impact on reducing the basic reproduction number $ R_0 $ compared to pulse vaccination. By analyzing key parameters such as $ R_0 $, pulse vaccination coefficients, and continuous vaccination parameters, the study underscores the value of mathematical modeling in shaping public health policies and guiding decision-making during disease outbreaks.
Chronic obstructive pulmonary disease (COPD) is a chronic lung inflammatory disease that causes restricted airflow and breathing difficulties. In this work, we attempted to explore the salutary effects of rutaecarpine on COPD-induced rats. Healthy Wistar rats were employed in this study and exposed to cigarette smoke to initiate COPD. The rutaecarpine was given to the rats at 20 and 30 mg/kg dosages, respectively, for 12 weeks. Body weight gain, food uptake, and food efficiency were assessed after treatment completion. The grip strength test was performed to assess muscle strength. The C-reactive protein (CRP), leptin, inflammatory cytokines, and oxidative stress markers were assessed using the corresponding assay kits. The inflammatory cells on the bronchoalveolar lavage fluid (BALF) were counted using Wright-Giemsa staining. The respiratory functions of the experimental rats were measured. The histopathological analysis was done on the lung tissues. The rutaecarpine treatment effectively increased body weight gain, food uptake, and food efficiency in the COPD rats. The levels of leptin were increased, and CRP was reduced by the rutaecarpine. The rutaecarpine regulated the respiratory functions and reduced the inflammatory cell counts and pro-inflammatory markers in the COPD rats. The levels of antioxidants were increased by the rutaecarpine treatment in the COPD rats. The findings of the lung histopathological study also demonstrated the therapeutic effects of rutaecarpine. Overall, the findings of the current study witness the salutary role of rutaecarpine against cigarette smoke-induced COPD in rats. Therefore, it was clear that rutaecarpine could be a promising salutary candidate to treat COPD.
BACKGROUND AND OBJECTIVE: Exposure to noise by generation of free radicals causes oxidative stress in body. The aim of this study was the evaluation of oxidative stress in workers who have used hearing protection devices during working time.
MATERIAL AND METHOD: Pressing workers (n=24) of a home appliance industry were studied using hearing protection devices to reduce noise exposure. Twenty two office staff (without exposure to noise) were considered as a control group. Two groups were matched for age, work experience and smoking. Exposure to noise was measured by dosimeter method at workstations. By obtaining 3 ml blood sample, Malondialdehyde levels, Thiol groups and total antioxidant capacity were evaluated in all subjects.
RESULTS: Exposure to sound pressure level in pressing workers by considering the noise reduction factor of the earplug was observed in 77.65 dB with minimum 75.1 dB and Maximum 81.22 dB. Plasma thiol groups (0.076 (0.041-0.119) vs (0.110 (0.076-0.197), mmol/l P =0.0001) and total antioxidant capacity (361.33± 54.65 vs 414.14± 96.82, µmol/ml P = 0.026) in pressing workers significantly decreased than control group. Pearson correlation showed significant results between exposure to noise and oxidative stress parameters.
CONCLUSION: Exposure to noise wave cause oxidative stress in different site of body. Oxidative stress is an intermediate way for different disease due to noise exposure. Reducing of noise exposure by earplug in pressing workers is not efficient protection for oxidative stress generation. Therefore, hearing protection devices are not a barrier to the harmful effects of noise in occupational exposure.
PURPOSE:To obtain a hair reproducing agent, containing extracts of aloe, ivy and hop, capable of treating premature baldness, reproducing hair, especially preventing male alopecia and useful for treating scalp hypersteatosis. CONSTITUTION:New buds of ivy and hop are collected and pressed to prepare respective extract solutions, which are separately preserved at 10 deg.C temperature for about 30 days. The supernatant liquids are then mixed and stirred with an extract pressed from leaves of aloe. The blending ratio is 70% aloe, 25% ivy and 5% hop. The mixture solution is then preserved at 10 deg.C temperature for further 30 days. A small amount of a perfume is then mixed with the above- mentioned supernatant liquid to afford the objective substance. The afore- mentioned supernatant liquid is applied to the bald surface part and continuously used.
This is a non-randomized, non-inferiority trial that has been created to compare results of achalasia procedures including but not limited to: POEM + Partial Fundoplication (PF), POEM and Laparoscopic Modified Heller Myotomy + PF and POEM + Peroral Plication of the esophagus. Using a set of consistent evaluation tools for patients undergoing treatment for achalasia allows a standardized evaluation and comparison of these groups of patients. The long term and comparative POEM procedure outcomes are not currently known. Patients undergoing POEM, fundoplication, and/or laparoscopic myotomy report having varying degrees of symptoms of reflux, dysphagia, and pain. Providers also note varying degrees of esophagitis by endoscopy, reflux by impedance or pH scoring, and recurrence by repeat manometry. Many of these issues can be quantified using pH probe testing, upper GI endoscopy, high resolution manometry, CT scans, Endoflip device and esophagrams. There are various validated questionnaires that have been used to assess problem areas of reflux, dysphagia, and pain such as the Promis Global Health Score, Ekhardt Score, Mayo GER Score, Modified Dysphagia Questionnaire-30 Day, Zubrod Score, and pain scale. Each of these symptoms, tests, and questionnaires contributes to the provider's understanding of the patient's postoperative outcome.
An embodiment of an analyte detection system includes a fluid transport network having a patient end configured to provide fluid communication with a body fluid in a patient. The system includes a body fluid analyzer, accessible via the fluid transport network, configured to measure a level of an analyte of interest in the body fluid. A pump unit having a sample input mode and an infusion mode may be coupled to the fluid transport network. The system also includes a user interface for communication with the body fluid analyzer. The user interface may include an input element (4946) configured to accept user input corresponding to a patient health event. In some embodiments, the patient health event includes a patient health action or information relevant to clinical interpretation of data pertaining to measured analyte levels. The user interface may include a trend display portion (4922) that includes a trend indicator,, which depicts a trend in determined levels of the analyte of interest. The trend display portion may also include at least one of a high-level indicator (4936) corresponding to a relatively high level of the analyte and a low-level indicator (4938) corresponding to a relatively low level of the analyte.
Participants with lower risk MDS that are transfusion dependent (TD). Participants will be asked to come to the study clinic weekly for the first 3 weeks and then 1 time every 3 weeks after that to have tests and procedures (such as physical exams and blood draws). Luspatercept will be administered once every 3 weeks.
OBJECTIVES: Mild cognitive impairment presenting with an amnestic syndrome (aMCI) and amyloid positivity is considered due to AD. Many subjects, however, can show an overall very slow progression relevant for differential diagnosis, prognosis, and treatment. This study assessed PET biomarkers, including brain glucose metabolism, tau, and amyloid load, in a series of comparable aMCI at baseline, clinically evaluated at follow-up.
METHODS: We included 72 aMCI subjects from Geneva Memory Center (N = 31) and ADNI cohorts (N = 41), selected based on available FDG-PET, tau-PET, amyloid-PET, and clinical follow-up (2.3 years ± 1.2). A data-driven algorithm classified brain metabolic patterns into subtypes that were then compared for clinical and PET biomarker measures and cognitive decline. Voxel-wise comparisons were performed both with FDG-PET and tau-PET data.
RESULTS: The algorithm classified three metabolic subtypes, namely "Hippocampal-sparing with cortical hypometabolism" (Type1; N = 27), "Hippocampal and cortical hypometabolism" (Type 2; N = 23), and "Medial temporal hypometabolism" (Type 3; N = 22). Amyloid positivity and tau accumulation in the medial temporal and neocortical regions characterized Type 1 and Type 2, whereas Type 3 showed no significant tau pathology, variable amyloid positivity, and stability at follow-up. All tau-positive patients, independently of the FDG-based subtype, showed faster cognitive decline.
INTERPRETATION: aMCI subjects can differ in metabolic patterns, tau and amyloid pathology, and clinical progression. Here, we complemented with PET tau biomarker the specific brain hypometabolic patterns at the individual level in the prodromal phase, contributing to the patient's classification. Tau PET is the most accurate biomarker in supporting or excluding the AD diagnosis in aMCI across metabolic subtypes and also predicting the risk of decline.
A harmless substance that looks like the study drug, but which should have no effect. The placebo formulation used in this study contains all the ingredients present in the active drug, except the active ingredient (IL-4α antibody). Therefore, the risk related to this formulation should be no greater than the risk associated to the active drug.
In treatment group, patients were given one to three sessions of External Physical Vibration Lithecbole therapy in two weeks. These patients were also instructed to drink a minimum of 2500 ml water daily and take more exercise.